Table 1.
Clinicopathological features of the 288 breast cancer patients.
Table 2.
The primers of AKT1 exon 3, KRAS exon2 and PIK3CA exons 4, 9 and 20.
Fig 1.
Immunohistochemistry of PTEN expression.
Depicted are photomicrographs of PTEN scoring: A, score 2 = same staining intensity as of surrounding normal epithelium; B, score 1 = weaker than normal; C, score 0 = no staining (× 100). The red arrow indicated the normal tissue.
Table 3.
Alterations of genes in 288 breast invasive ductal carcinomas.
Table 4.
Correlation between clinicopathological features and PAM pathway activation, PIK3CA mutation and PTEN loss.
Fig 2.
Correlation between PI3K/AKT/mTOR pathway alterations and prognosis by Kaplan–Meier survival analysis.
A. PAM activation vs. normal PAM in all patients; B. PTEN loss vs. normal PTEN in all patients; C. mutant PIK3CA vs. normal PIK3CA in all patients; D. mutant PIK3CA vs. normal PIK3CA in ER positive patients.
Table 5.
Correlation between PIK3CA mutation and clinicopathologic characteristics of 152 ER-positive sporadic breast cancer patients.
Table 6.
PIK3CA mutation in 152 ER positive breast cancers.
Table 7.
Clinicopathological features of 48 relapsed patients vs. 75 relapse-free patients.
Table 8.
Correlation between PIK3CA, KRAS/PIK3CA/AKT mutation and hormone receptor status of 48 relapsed patients.